Promising immunotherapy for ‘difficult to treat’ lung cancer patients

iStock.com/gevende

An immunotherapy for a difficult to treat lung cancer has shown promise after it improved overall survival, British researchers reported today.

A global study, led by University College London and its associated hospital group, found that compared to single-agent chemotherapy, atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer (NSCLC) patients who were not able to be treated with platinum-containing chemotherapy.